Case Study
High-Volume Patient Narratives: When Agile Solutions And Expertise Matter Most
Global pharmaceutical company partners with IQVIA to address medical writing patient narrative preparation needs for accelerated COVID-19 vaccine trial with stringent timeframe for regulatory review.
Apr 06, 2022

As the global healthcare industry diligently worked to diminish the impact of the pandemic worldwide, many pharmaceutical companies accelerated research for COVID-19 vaccines. It was key for every component of clinical development to work with efficiency, collaboration, innovation and experience, given the time sensitivities around the need for effective vaccines viable options.

A global pharmaceutical company realized that their initial narrative vendor could not deliver the growing volume of narratives within the planned timelines. Also working with multiple functions and units across the full enterprise to rapidly develop a COVID-19 vaccine for potential emergency use authorization (EUA), the company selected the IQVIA Medical Writing team to oversee their development and delivery for an interim analysis. The IQVIA Medical Writing team quickly initiated the work and successfully delivered all requested text narratives (>1,000) in the short time span of four weeks and ahead of schedule, leveraging innovative tech-enabled processing solutions combined with medical writing narrative expertise.

Related solutions

Contact Us